Skip to content

Evaluating Mental Health Challenges in Juvenile Lupus Erythematosus and Their Caregivers

Evaluating Mental Health Challenges in Juvenile Lupus Erythematosus and Their Caregivers

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06581029
Enrollment
62
Registered
2024-08-30
Start date
2025-06-01
Completion date
2026-12-30
Last updated
2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SLE

Brief summary

assessment of psychiatric problems in pediatric SLE and their caregivers. evaluate the possible risk factors of psychiatric problems such as peer victimization, academic performance, fatigue, self-esteem and quality of life.

Detailed description

Juvenile-onset systemic lupus erythematosus (jSLE) is a rare but severe multisystem autoimmune disease which may cause significant damage, disability, and death . Juvenile SLE patients constitute 15-20% of all SLE cases . Compared to the adult SLE, jSLE patients have higher morbidity and mortality rates. Renal, cardiovascular, and neuropsychiatric (NP) involvements are the most important reasons for morbidity and mortality . Therefore, knowledge of common mental illnesses such as major depressive disorder (MDD) and anxiety disorders in cSLE may be limited. Establishing the prevalence of MDD and anxiety in cSLE is important , as comorbidity rates of these disorders may be increased in cSLE for several reasons. First, the diagnosis of a serious physical health condition confers psychological vulnerability to feelings of sadness, helplessness, stress, and worry about the future.9 For some individuals, such symptoms warrant further evaluation and may persist beyond the initial adjustment period and reach clinical significance, requiring therapeutic intervention. SLE carries a patient-treatment burden similar to other chronic diseases. Such treatment burden places susceptible individuals at risk of psychiatric disorder. Second, although depressed mood may present in the absence of active CNS disease, it may also occur as a symptom of neuropsychiatric c SLE (NPSLE), yielding clinically significant treatment implications. Third, treatment of SLE with known depressogenic medications like steroid may lead to depressive symptom elevation or exacerbate a co-morbid primary MDD. Moreover, among patients with depressed mood as a manifestation of NPSLE, the initiation of steroid treatment may worsen depressive symptoms. It is unclear whether such risks are observed in the cSLE population.

Interventions

OTHERThe multidimensional peer victimization scale (PVS)

The multidimensional peer victimization scale (PVS), a self-report scale for children and adolescents, was used to assess the victimization

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
11 Years to 18 Years

Inclusion criteria

1. Age from 11 to 18 years 2. Both sex 3. diagnosed with SLE for at least 6 months to allow for an adjustment period following diagnosis. 4. Met the New ACR and EULAR criteria for classification of SLE . Inclusion criteria of the control healthy group : 1- no history of psychiatric and medical disease 2-Intelligence quotation more than 70.

Exclusion criteria

1. No history of psychiatric illness prior to the diagnosis of lupus. 2. Intelligence quotation more than 70.

Design outcomes

Primary

MeasureTime frameDescription
Evaluating mental health challenges in juvenile SLE and their caregiversbaselineThe aim of the present study is to evaluate and assess psychiatric problems in juvenile systemic lupus erythematosus patients and their caregivers. Also, to evaluate the possible risk factors of psychiatric problems such as peer victimization, academic performance, fatigue, self-esteem and quality of life.

Contacts

Primary ContactSahar Samir, resident
samirsamar936@gmail.com01067046915
Backup ContactNaglaa Samy, Associate proff
Naglaaosman84@aun.edu.eg01002673103

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026